TransMedics Group, Inc. (TMDX): Price and Financial Metrics
TMDX Price/Volume Stats
| Current price | $156.08 | 52-week high | $177.37 |
| Prev. close | $151.21 | 52-week low | $36.42 |
| Day low | $152.30 | Volume | 821,900 |
| Day high | $156.95 | Avg. volume | 773,351 |
| 50-day MA | $154.00 | Dividend yield | N/A |
| 200-day MA | $113.22 | Market Cap | 5.14B |
TMDX Stock Price Chart Interactive Chart >
TransMedics Group, Inc. (TMDX) Company Bio
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
Latest TMDX News From Around the Web
Below are the latest news stories about TRANSMEDICS GROUP INC that investors may wish to consider to help them evaluate TMDX as an investment opportunity.
Fund manager's top growth stock picks for 2024As 2023 comes to a close, Clough Capital CEO and President Vince Lorusso discusses his top stock picks as we move into the new year. When discussing the funds he manages, Lorusso says, "There's really two different areas of investments. I kind of characterize them as stable growth companies, meaning they might be a little bit more defensive if we do have a little bit of a slowdown in the consumer." Lorusso's top picks for stable growth include Service Corporation International (SCI), Rollins, Inc. (ROL), and gold miners and utilities sectors. "In the other part of the portfolio, are these more dynamic growth companies that we think do have more beta potentially and are most exposed to some of the secular and also cyclical enthusiasm we're seeing around things like AI and EVs." Lorusso's... |
TransMedics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceTransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 8, 2024, at 3:00 p.m. Pacific Standard Time / 6:00 p.m. Eastern Standard Time. |
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 7, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 9,547 shares of its common stock and an aggregate of 6,175 restricted stock units to 11 employees, each as a material inducement for each employee's entry into employment with TransMedics. Th |
Got $2,000? 3 Growth Stocks to Buy That Could Double Your MoneyHere are three stocks to buy that could double your money. If Wall Street is right, Madrigal Pharmaceuticals (NASDAQ: MDGL) stock could go a long way toward doubling your money over the next 12 months. Madrigal could win U.S. Food and Drug Administration (FDA) approval for resmetirom in treating nonalcoholic steatohepatitis (NASH) by March 14, 2024. |
Investing in These 3 Stocks Now Could Make You a Millionaire RetireeLet me be clear upfront. To have a decent chance of retiring with $1 million or more, you're going to need cash to invest and plenty of time. Exactly how much cash and how much time is required will vary. |
TMDX Price Returns
| 1-mo | -6.58% |
| 3-mo | 8.39% |
| 6-mo | 120.27% |
| 1-year | 166.67% |
| 3-year | 392.37% |
| 5-year | 531.14% |
| YTD | 97.74% |
| 2023 | 27.88% |
| 2022 | 222.13% |
| 2021 | -3.72% |
| 2020 | 4.68% |
| 2019 | N/A |
Loading social stream, please wait...